ArticleClinicoEconomics and outcomes research : CEOR2020

Budget Impact Analysis of Switching to Rituximab's Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa.

Ammar AlmaaytahPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.